How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and ...

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Walgreens adds GLP-1 coverage navigation, Medicare Bridge support and pharmacist outreach to its virtual weight management ...

BMS’s Kevin Cook explains why digital capability is becoming a must-have for strategic CMO partners and why the next phase ...

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean ...

Real-world evidence is increasingly valuable when it measurably changes clinical actions, not only when it supports publications, retrospective analyses or regulatory submissions. Information overload ...